Answers are grounded in this paper and cite their sources.
The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected price reductions, shifts in prescribing toward more expensive brand-name treatments, and limited uptake of the generic product.
No takes yet. Share an insight, caveat, or question.
Cole et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: